Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | TLR4 | O00206 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965482 | 1.00 | ELANE (0.39) | ELANETLR4OPRK1MEN1TSHR | |
| SCHEMBL3635011 | 0.88 | OPRK1 (0.33) | ELANETLR4OPRK1HTTPOLB | |
| SCHEMBL17788020 | 0.83 | OPRK1 (0.35) | OPRK1MEN1TSHRHTTKMT2A | |
| SCHEMBL9965481 | 0.81 | ATM (0.45) | ELANEMEN1KMT2A | |
| SCHEMBL5137199 | 0.81 | SMN1; SMN2 (0.40) | MEN1TSHRKMT2APOLB | |
| SCHEMBL642245 | 0.81 | ATM (0.45) | ELANEMEN1KMT2A | |
| SCHEMBL17317470 | 0.78 | OPRK1 (0.34) | OPRK1 | |
| Benzene SCHEMBL27759722 | 0.76 | ALDH1A1 (0.45) | MEN1TSHRHTTKMT2APOLB | |
| SCHEMBL19097297 | 0.72 | ATM (0.52) | MEN1KMT2A | |
| SCHEMBL10174355 | 0.71 | SMN1; SMN2 (0.37) | POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023710-A1 | Compound | NR1H3, NR1H2, NR1H4 | ELANE 4457/4885TLR4 1931/4885OPRK1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.